1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Mannose Phosphate Isomerase Deficiency - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Mannose Phosphate Isomerase Deficiency - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Mannose Phosphate Isomerase Deficiency - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2017-2033)
7.2.4 Epidemiology by Gender (2017-2033)
7.2.5 Diagnosed Cases (2017-2033)
7.2.6 Patient Pool/Treated Cases (2017-2033)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2017-2033)
7.3.4 Epidemiology by Gender (2017-2033)
7.3.5 Diagnosed Cases (2017-2033)
7.3.6 Patient Pool/Treated Cases (2017-2033)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2017-2033)
7.4.4 Epidemiology by Gender (2017-2033)
7.4.5 Diagnosed Cases (2017-2033)
7.4.6 Patient Pool/Treated Cases (2017-2033)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2017-2033)
7.5.4 Epidemiology by Gender (2017-2033)
7.5.5 Diagnosed Cases (2017-2033)
7.5.6 Patient Pool/Treated Cases (2017-2033)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2017-2033)
7.6.4 Epidemiology by Gender (2017-2033)
7.6.5 Diagnosed Cases (2017-2033)
7.6.6 Patient Pool/Treated Cases (2017-2033)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2017-2033)
7.7.4 Epidemiology by Gender (2017-2033)
7.7.5 Diagnosed Cases (2017-2033)
7.7.6 Patient Pool/Treated Cases (2017-2033)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2017-2033)
7.8.4 Epidemiology by Gender (2017-2033)
7.8.5 Diagnosed Cases (2017-2033)
7.8.6 Patient Pool/Treated Cases (2017-2033)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2017-2033)
7.9.4 Epidemiology by Gender (2017-2033)
7.9.5 Diagnosed Cases (2017-2033)
7.9.6 Patient Pool/Treated Cases (2017-2033)
8 Mannose Phosphate Isomerase Deficiency - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Mannose Phosphate Isomerase Deficiency - Unmet Needs
10 Mannose Phosphate Isomerase Deficiency - Key Endpoints of Treatment
11 Mannose Phosphate Isomerase Deficiency - Marketed Products
11.1 List of Mannose Phosphate Isomerase Deficiency Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 Mannose Phosphate Isomerase Deficiency - Pipeline Drugs
12.1 List of Mannose Phosphate Isomerase Deficiency Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. Mannose Phosphate Isomerase Deficiency - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Mannose Phosphate Isomerase Deficiency – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Mannose Phosphate Isomerase Deficiency - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Mannose Phosphate Isomerase Deficiency - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Mannose Phosphate Isomerase Deficiency - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Mannose Phosphate Isomerase Deficiency - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Mannose Phosphate Isomerase Deficiency - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Mannose Phosphate Isomerase Deficiency - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Mannose Phosphate Isomerase Deficiency - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Mannose Phosphate Isomerase Deficiency - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Mannose Phosphate Isomerase Deficiency - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Mannose Phosphate Isomerase Deficiency - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Mannose Phosphate Isomerase Deficiency - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Mannose Phosphate Isomerase Deficiency - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Mannose Phosphate Isomerase Deficiency - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Mannose Phosphate Isomerase Deficiency - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Mannose Phosphate Isomerase Deficiency - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Mannose Phosphate Isomerase Deficiency - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Mannose Phosphate Isomerase Deficiency - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Mannose Phosphate Isomerase Deficiency - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Mannose Phosphate Isomerase Deficiency - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Mannose Phosphate Isomerase Deficiency - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Mannose Phosphate Isomerase Deficiency - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Mannose Phosphate Isomerase Deficiency - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Mannose Phosphate Isomerase Deficiency - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Mannose Phosphate Isomerase Deficiency - Access and Reimbursement Overview
16 Mannose Phosphate Isomerase Deficiency - Recent Events and Inputs From Key Opinion Leaders
17 Mannose Phosphate Isomerase Deficiency Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Mannose Phosphate Isomerase Deficiency Market – Strategic Recommendations
19 Appendix